X4 Pharmaceuticals (XFOR)

• Market cap: $320M
• 1 day: 1.25%
• 5 days: 8.31%
• 1 month: 18.13%
• 3 months: 140.48%
• 6 months: -6.26%
• Year to date: -82.09%
• 1 year: -73.08%
• 5 years: -97.75%
• 10 years: -99.84%
• Sector: Healthcare
• Industry: Biotechnology

About: X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Employees: 143